Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Dana farber Cancer Institute Inc patents


Recent patent applications related to Dana farber Cancer Institute Inc. Dana farber Cancer Institute Inc is listed as an Agent/Assignee. Note: Dana farber Cancer Institute Inc may have other listings under different names/spellings. We're not affiliated with Dana farber Cancer Institute Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Dana farber Cancer Institute Inc-related inventors


Method for preparing largazole analogs and uses thereof

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.... Dana farber Cancer Institute Inc

Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

The present disclosure is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.... Dana farber Cancer Institute Inc

Structured viral peptide compositions and methods of use

The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant... Dana farber Cancer Institute Inc

Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof

The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.... Dana farber Cancer Institute Inc

Methods to induce targeted protein degradation through bifunctional molecules

The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted... Dana farber Cancer Institute Inc

Methods for profiling the t cell repertoire

The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T... Dana farber Cancer Institute Inc

Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents

The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.... Dana farber Cancer Institute Inc

Immunomodulation by iap inhibitors

The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating... Dana farber Cancer Institute Inc

Kinase inhibitors for the treatment of disease

The invention relates to compounds and their use in the treatment of disease. Novel irreversible inhibitors of wild-type and mutant forms of EGFR, FGFR, ALK, ROS, JAK, BTK, BLK, ITK, TEC, and/or TXK and their use for the treatment of cell proliferation disorders are described.... Dana farber Cancer Institute Inc

Microfluidic cell culture of patient-derived tumor cell spheroids

Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 μm to... Dana farber Cancer Institute Inc

Systems and methods for genome modification and regulation

The present invention provides methods of systems and methods of site specific methylation.... Dana farber Cancer Institute Inc

Rapid quantitative detection of single nucleotide polymorphisms or somatic variants and methods to identify malignant neoplasms

Provided are systems, kits, and methods for the quantitative detection of single nucleotide polymorphisms or variants to identify malignant neoplasms. The methods include use of modified oligonucleotide blockers with peptide nucleic acid backbones that hybridize to and block logarithmic amplification of the wild-type alleles of a target, and incorporation of... Dana farber Cancer Institute Inc

Histone deacetylase inhibitors

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an... Dana farber Cancer Institute Inc

Bromodomain inhibitor as adjuvant in cancer immunotherapy

Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject... Dana farber Cancer Institute Inc

In vivo methods for identifying cancer-associated immunotherapy targets

The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.... Dana farber Cancer Institute Inc

Novel pyrimidines as egfr inhibitors and methods of treating disorders

which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.... Dana farber Cancer Institute Inc

Chimeric antigen receptors and methods of use thereof

The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.... Dana farber Cancer Institute Inc

Compositions and methods for treating multiple myeloma

The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in... Dana farber Cancer Institute Inc

Multiple-variable il-2 dose regimen for treating immune disorders

The present invention is based, in part, on the identification of iiicihods of using multiple-variable IL-2 doses for identifying, assessing, preventing, and treating immune disorders.... Dana farber Cancer Institute Inc

Small molecule myristate inhibitors of bcr-abl and abl and methods of use

The present invention provides novel heteroaryl compounds of formula (I) having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers.... Dana farber Cancer Institute Inc

Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereof

Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell... Dana farber Cancer Institute Inc

Sik inhibitor for use in a treating an inflammatory and/or immune disorder

The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or... Dana farber Cancer Institute Inc

Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses

The present invention is based on the identification of novel biomarkers predictive of responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.... Dana farber Cancer Institute Inc

Hck as a therapeutic target in myd88 mutated diseases

Methods of treatment of conditions or diseases associated with myeloid differentiation primary response (MYD88) protein using a selective HCK inhibitor are provided herein.... Dana farber Cancer Institute Inc

Apparatus and isolating target cells from a fluid sample

Systems, methods, and apparatus are disclosed for recovering one or more target cells from a fluid sample. A first chamber aligned with a first surface of a removable filter receives the fluid sample. The removable filter defines a plurality of pores configured to retain the one or more target cells... Dana farber Cancer Institute Inc

Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof

The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.... Dana farber Cancer Institute Inc

Methods for discovering therapeutics that alter the stability of target proteins

The present application relates, in some aspects, to screening methods to identify test compounds that stabilize or destabilize a protein of interest. The present application is based, in some aspects, on the development of a plasmid that can be used to efficiently monitor the stabilities of thousands of proteins after... Dana farber Cancer Institute Inc

Compositions and methods for treating malignancies

Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form... Dana farber Cancer Institute Inc

Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients

The present invention generally relates to the methods and use of clonal evolution analysis of the kinetics and genetic alterations associated with the development of resistance to a therapy using whole-exome and deep targeted sequencing in treating patients in need thereof.... Dana farber Cancer Institute Inc

Small molecule inhibitors of hiv-1 entry and methods of use thereof

Described herein are small-molecule compounds that specifically inhibit a wide range of HIV-1 isolates without interfering with CD4 or CCR5 binding. Methods of using die compounds for treating or preventing HIV infection are also described.... Dana farber Cancer Institute Inc

Methods for predicting the risk of developing breast cancer

The present invention provides methods for accessing the risk of developing breast cancer.... Dana farber Cancer Institute Inc

Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce... Dana farber Cancer Institute Inc

Plasmids comprising internal ribosomal entry sites and uses thereof

The present application relates, in some aspects, to the development of a plasmid that can be used to efficiently monitor the stabilities of thousands of proteins after specific perturbations. The plasmid allows for the co-expression of two reporter proteins, each of which is placed under the control of an IRES.... Dana farber Cancer Institute Inc

Pyrimido-diazepinone compounds and methods of treating disorders

The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1,... Dana farber Cancer Institute Inc

09/21/17 / #20170266123

Coated particles for drug delivery

In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more components, such as two pharmaceutically active agents or a pharmaceutically active... Dana farber Cancer Institute Inc

09/21/17 / #20170267630

Class-and isoform-specific hdac inhibitors and uses thereof

HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain... Dana farber Cancer Institute Inc

09/21/17 / #20170269076

Intracellular osteopontin regulates the lineage commitment of lymphoid subsets

Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide... Dana farber Cancer Institute Inc

09/14/17 / #20170260208

Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders

The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2,... Dana farber Cancer Institute Inc

09/14/17 / #20170260248

Stabilized insulinotropic peptides and methods of use

The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and... Dana farber Cancer Institute Inc

08/31/17 / #20170247423

Stapled intracellular-targeting antimicrobial peptides to treat infection

Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.... Dana farber Cancer Institute Inc

08/31/17 / #20170247456

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.... Dana farber Cancer Institute Inc

08/31/17 / #20170248603

Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.... Dana farber Cancer Institute Inc

08/24/17 / #20170240632

Compositions and methods for identifying and treating cachexia or pre-cachexia

The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with one or more pre-cachexia and/or cachexia-associated RAGE ligands or markers.... Dana farber Cancer Institute Inc

08/17/17 / #20170233335

Inhibitors of hiv-1 entry and methods of use thereof

The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to... Dana farber Cancer Institute Inc

08/17/17 / #20170233411

Thiazolyl-containing compounds for treating proliferative diseases

The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma... Dana farber Cancer Institute Inc

08/17/17 / #20170233808

Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.... Dana farber Cancer Institute Inc

08/10/17 / #20170224700

Uses of salt-inducible kinase (sik) inhibitors

The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK... Dana farber Cancer Institute Inc

08/10/17 / #20170224732

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and... Dana farber Cancer Institute Inc

08/10/17 / #20170224793

Tumor immunity

Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided.... Dana farber Cancer Institute Inc

08/03/17 / #20170215392

Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo

The invention provides methods and compositions for perturbing gene expression in hematopoietic cell lineages in vivo.... Dana farber Cancer Institute Inc

07/27/17 / #20170209458
07/27/17 / #20170209601

Biopolymer-nanoparticle composite implant for tumor cell tracking

A method of detecting migration of tumor cells is provided by implanting in a region of tumor cells one or more implants having a matrix material of a biocompatible and biodegradable polymer, and a plurality of nanoparticles dispersed within the matrix material and functionalized to bind tumor cells. Nanoparticles bound... Dana farber Cancer Institute Inc

07/20/17 / #20170202810

Small molecule inhibitors of usp1 deubiquitinating enzyme activity

Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.... Dana farber Cancer Institute Inc

07/20/17 / #20170204082

Imidazolyl kinase inhibitors and uses thereof

The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease... Dana farber Cancer Institute Inc

07/20/17 / #20170204116

Macrocyclic kinase inhibitors and uses thereof

The present disclosure provides macrocyclic compounds of Formula (I). The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological... Dana farber Cancer Institute Inc

07/13/17 / #20170198039

Methods for treating cancer

The present invention provides methods of treating cancer, particularly cancers that had developed resistance to PD-1 and PDL-1 blockade. Also included are methods of identifying therapeutic targets for the treatment of cancer.... Dana farber Cancer Institute Inc

07/13/17 / #20170198041

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.... Dana farber Cancer Institute Inc

07/06/17 / #20170190777

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.... Dana farber Cancer Institute Inc

06/29/17 / #20170182119

Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin

Described herein are methods of modulating autophagic targeting of ferritin in a cell, wherein the method comprises modulating the level and/or activity of nuclear receptor coactivator 4 (NCOA4) in the cell. Also provided are related methods of treatment.... Dana farber Cancer Institute Inc

06/29/17 / #20170184565

P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses

The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.... Dana farber Cancer Institute Inc

06/29/17 / #20170184567

Methods of determining cellular chemosensitivity

The present invention provides methods of determining cell sensitivity to a therapeutic agent.... Dana farber Cancer Institute Inc

06/22/17 / #20170173083

Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells

Described herein are methods and compositions which lead to the efficient ex vivo expansion of hematopoietic cells, such as hematopoietic stem cells (HSCs) and hematopoietic stem and progenitor cells HSPCs. Using combinations of small molecule drugs and cytokines/growth factors/grown factors targeting epigenetic status in cells, significant improvements in the expansion... Dana farber Cancer Institute Inc

06/22/17 / #20170174751

Immunogenetic restriction on elicitation of antibodies

The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an... Dana farber Cancer Institute Inc

06/08/17 / #20170158752

Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.... Dana farber Cancer Institute Inc

Patent Packs
06/08/17 / #20170160267

Methods of determining cellular chemosensitivity

... Dana farber Cancer Institute Inc

05/25/17 / #20170145013

Dihydropteridinone derivatives and uses thereof

The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g.,... Dana farber Cancer Institute Inc

05/25/17 / #20170145023

Diazepane derivatives and uses thereof

The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g.,... Dana farber Cancer Institute Inc

05/25/17 / #20170146520

Methods for the treatment of infections and tumors

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus,... Dana farber Cancer Institute Inc

05/18/17 / #20170137766

Systems, apparatus, and methods related to magnetically-controlled three-dimensional tissue cultures

Systems, devices, and methods for generating, culturing, and using magnetically-controlled three-dimensional (3D) tissues are described. A magnetically-enabled transwell system for immobilizing and supplying perfusion to a 3D mini-tissue includes a cell culture vessel with at least a first chamber and a second chamber, the mini-tissue being disposed in the first... Dana farber Cancer Institute Inc

05/11/17 / #20170130271

Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.... Dana farber Cancer Institute Inc

04/27/17 / #20170112777

Protein-based particles for drug delivery

In one aspect, a method for forming particles is provided. The method may allow biocompatible particles comprising an agent (e.g., pharmaceutically active agent) to be produced absent one or more purification step (e.g., removal of excess reagent). In certain embodiments, particles, produced as described herein, can be utilized in a... Dana farber Cancer Institute Inc

04/27/17 / #20170114323

Uses of kinase inhibitors for inducing and maintaining pluripotency

The present disclosure provides compounds of any one of Formulae (A) to (L). The present disclosure also provides compositions, uses, and methods that include or involve a compound described herein, a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor 1 (VEGFR1)... Dana farber Cancer Institute Inc

04/27/17 / #20170114413

Compositions and methods for targeting cancer-specific sequence variations

The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or... Dana farber Cancer Institute Inc

04/27/17 / #20170115291

Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.... Dana farber Cancer Institute Inc

03/23/17 / #20170081379

Stabilized p53 peptides and uses thereof

Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.... Dana farber Cancer Institute Inc

03/23/17 / #20170081724

Method and kits for determining sensitivity to cancer treatment

A method of increasing the efficacy of treatment for a patient suffering from urothelial carcinoma. The method comprises the steps of determining the presence or absence in a biological sample from the patient of somatic ERCC2 mutation followed by performing appropriate treatment. The absence of somatic ERCC2 mutation indicates that... Dana farber Cancer Institute Inc

03/16/17 / #20170072028

Compositions and methods for regulating pancreatic beta cell function using adipsin

The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.... Dana farber Cancer Institute Inc

03/16/17 / #20170073431

Humanized monoclonal antibodies and methodsof use

The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.... Dana farber Cancer Institute Inc

03/09/17 / #20170065676

Bpi and its congeners as radiation mitigators and radiation protectors

Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.... Dana farber Cancer Institute Inc

Patent Packs
03/02/17 / #20170056471

Bpi and its congeners as radiation mitigators and radiation protectors

Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.... Dana farber Cancer Institute Inc

02/23/17 / #20170051030

Fusion proteins for treating cancer and related methods

Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer.... Dana farber Cancer Institute Inc

02/23/17 / #20170051358

Compositions and methods for identification, assessment, prevention, and treatment of cancer using nfs1 biomarkers and modulators

The present invention is based, in part, on the identification, of novel mitochondrial iron-sulfur (Fe—S) cluster biosynthesis pathway biomarkers and modulators, and methods of use thereof, for identifying, assessing, preventing, and treating cancer.... Dana farber Cancer Institute Inc

02/16/17 / #20170042995

Combination vaccine devices and methods of killing cancer cells

The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.... Dana farber Cancer Institute Inc

02/16/17 / #20170044111

Janus kinase inhibitors and uses thereof

The present invention provides kinase inhibitors, such as compounds of Formula (I) and Formula (II). The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and/or... Dana farber Cancer Institute Inc

02/16/17 / #20170044112

Hydrophobically tagged janus kinase inhibitors and uses thereof

The present invention provides Janus kinase inhibitors, such as compounds of Formula (I) and Formula (II) wherein RY1 and RY2 comprise a tagged hydrophobic moiety RH. The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). The hydrophobic moiety RH may signal to the intracellular protein... Dana farber Cancer Institute Inc

02/16/17 / #20170044262

Humanized monoclonal antibodies and methods of use

The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used... Dana farber Cancer Institute Inc

02/16/17 / #20170045506

High-throughput structure determination using nucleic acid calipers

Provided herein are compositions and methods for determining the structure of individual targets using nucleic acid caliper by determining long-range distances within such targets.... Dana farber Cancer Institute Inc

02/09/17 / #20170037478

Methods for predicting anti-cancer response

The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.... Dana farber Cancer Institute Inc

02/02/17 / #20170029437

Compositions and methods for treating neoplasia, inflammatory disease and other disorders

The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).... Dana farber Cancer Institute Inc

02/02/17 / #20170029903

Ddr2 mutations in squamous cell lung cancer

Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.... Dana farber Cancer Institute Inc

01/26/17 / #20170022275

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).... Dana farber Cancer Institute Inc

01/19/17 / #20170015716

Stabilized anti-microbial peptides

The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.... Dana farber Cancer Institute Inc

01/12/17 / #20170008895

Uses of diazepane derivatives

The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical... Dana farber Cancer Institute Inc

01/12/17 / #20170008962

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.... Dana farber Cancer Institute Inc

01/05/17 / #20170000867

Vaccine compositions and methods for restoring nkg2d pathway function against cancers

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.... Dana farber Cancer Institute Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Dana farber Cancer Institute Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dana farber Cancer Institute Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###